- Q1 2024 Viridian Therapeutics Inc Earnings Call TranscriptMay 08, 2024$14.9 (-1.59%)Earnings
- Viridian Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Viridian Therapeutics Inc Subcutaneous IGF-1R Program Selection TranscriptDec 18, 2023
- Viridian Therapeutics Inc VRDN-001 Chronic TED Data Conference Call TranscriptJul 10, 2023
- Q1 2023 Viridian Therapeutics Inc Earnings Call TranscriptMay 09, 2023$25.68 (+0.75%)Earnings
- Q4 2022 Viridian Therapeutics Inc Earnings Call TranscriptMar 08, 2023$29.47 (-10.48%)Earnings
- Viridian Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Q3 2022 Viridian Therapeutics Inc Earnings Call TranscriptNov 14, 2022$20.32 (-0.93%)Earnings
- Q2 2022 Viridian Therapeutics Inc Earnings Call TranscriptAug 15, 2022$22 (+49.36%)Earnings
- Q1 2022 Viridian Therapeutics Inc Earnings Call TranscriptMay 12, 2022$10.56 (+5.49%)Earnings
- Q4 2021 Viridian Therapeutics Inc Earnings Call TranscriptMar 10, 2022$19.04 (-3.05%)Earnings
- Viridian Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Viridian Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Q4 2020 Viridian Therapeutics Inc Earnings Call TranscriptMar 25, 2021$17.27 (-1.26%)Earnings
- Viridian Therapeutics Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 03, 2021
- miRagen Therapeutics Inc Extraordinary Shareholders Meeting TranscriptDec 31, 2020
- Miragen Therapeutics, Inc., Viridian Therapeutics, Inc. - M&A Call TranscriptOct 28, 2020
- Q2 2020 miRagen Therapeutics Inc Earnings Call TranscriptAug 05, 2020$17.55 (+2.63%)Earnings
- Miragen Therapeutics - Special Call TranscriptJun 23, 2020
- miRagen Therapeutics Inc Annual Shareholders Meeting TranscriptMay 21, 2020
- Q1 2020 miRagen Therapeutics Inc Earnings Call TranscriptMay 07, 2020$8.25 (-3.51%)Earnings
- Q4 2019 miRagen Therapeutics Inc Earnings Call TranscriptMar 11, 2020$9.18 (-8.44%)Earnings
- Miragen Therapeutics, Inc. - Special Call TranscriptDec 11, 2019
- Q3 2019 miRagen Therapeutics Inc Earnings Call TranscriptNov 07, 2019$10.68 (-3.78%)Earnings
- Q2 2019 miRagen Therapeutics Inc Earnings Call TranscriptAug 07, 2019$23.55 (+18.05%)Earnings
- miRagen Therapeutics Inc Annual Shareholders Meeting TranscriptJun 19, 2019
- Q1 2019 miRagen Therapeutics Inc Earnings Call TranscriptMay 08, 2019$42.15 (-0.35%)Earnings
- Q4 2018 miRagen Therapeutics Inc Earnings Call TranscriptMar 13, 2019$39.75 (+3.52%)Earnings
Miragen Therapeutics - Special Call Transcript
Good day and welcome to the KOL call on MRG-229 for the treatment of idiopathic pulmonary fibrosis hosted by Miragen Therapeutic, Inc.
I'll now turn the call over to Dr. Bill Marshall, Chief Executive Officer of Miragen Therapeutics. Please go ahead, sir.
Thank you very much. Good morning, everyone, and thank you for joining us for this key opinion leader call on MRG-229. We're happy to be able to host this webinar call this morning and fortunate to have a couple of very important key opinion leaders in this area join us today for a discussion of some recent discoveries that we've made at Miragen Therapeutics that we believe are going to be important -- potentially important in the future treatment of idiopathic pulmonary fibrosis in the development of MRG-229.
Joining us today is Naftali Kaminski. Naftali is the Boehringer-Ingelheim Endowed Chair -- Endowed Professor of Internal Medicine and Chief of Pulmonary and Critical Care and Sleep Medicine at
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)